Gregor Jost Selected Research

iopromide (Ultravist)

12/2020	Contrast Saline Mixture DualFlow Injection Protocols for Low-Kilovolt Computed Tomography Angiography: A Systematic Phantom and Animal Study.
1/2020	Effect of Gadoxetic Acid Injection Duration on Tumor Enhancement in Arterial Phase Liver MRI.
12/2016	Characterization of a Novel Hafnium-Based X-ray Contrast Agent.
12/2014	Adverse skin reactions to iodinated x-ray contrast agents in healthy rats.
10/2013	Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics.
5/2012	Impact of iso- and low-osmolar iodinated contrast agents on BOLD and diffusion MRI in swine kidneys.
4/2012	Contrast timing in computed tomography: effect of different contrast media concentrations on bolus geometry.
12/2011	Changes of renal water diffusion coefficient after application of iodinated contrast agents: effect of viscosity.
4/2011	Low-osmolar monomeric versus iso-osmolar dimeric contrast media: an intra-individual comparison in CT angiography using an animal model.
4/2011	Computed tomography angiography: the effect of different chaser flow rates, volumes, and fluids on contrast enhancement.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregor Jost Research Topics

Disease

21	Body Weight (Weight, Body) 10/2022 - 02/2009
10	Neoplasms (Cancer) 10/2022 - 06/2009
4	Nephrogenic Fibrosing Dermopathy 01/2017 - 06/2009
2	Glioblastoma (Glioblastoma Multiforme) 10/2022 - 05/2003
2	Brain Neoplasms (Brain Tumor) 11/2019 - 01/2017
2	Glioma (Gliomas) 08/2014 - 05/2003
2	Hypoxia (Hypoxemia) 05/2012 - 02/2009
1	Coronary Stenosis (Coronary Artery Stenosis) 01/2021
1	Pathologic Constriction (Stenosis) 01/2021
1	Gliosarcoma 11/2019
1	Angioedema 12/2014
1	Pulmonary Embolism 08/2013
1	Acute Kidney Injury (Acute Renal Failure) 09/2012
1	Carcinoma (Carcinomatosis) 04/2012
1	Neoplasm Metastasis (Metastasis) 08/2011
1	Renal Insufficiency (Renal Failure) 05/2010
1	Myocardial Infarction 02/2009
1	Infarction (Infarctions) 02/2009
1	Chromosome Aberrations (Chromosome Abnormalities) 02/2009
1	Phenylketonurias (Phenylketonuria) 08/2005
1	Lymphoma (Lymphomas) 05/2003
1	Astrocytoma (Pilocytic Astrocytoma) 05/2003

Drug/Important Bio-Agent (IBA)

15	IodineIBA 01/2022 - 02/2009
11	Contrast MediaIBA 01/2021 - 02/2009
11	iopromide (Ultravist)FDA Link 12/2020 - 02/2009
5	gadobutrolIBA 10/2022 - 05/2018
5	GadoliniumIBA 11/2019 - 06/2009
5	iodixanol (Visipaque)FDA Link 12/2014 - 02/2009
3	gadodiamide (Omniscan)FDA Link 01/2022 - 01/2011
3	gadolinium ethoxybenzyl DTPA FDA Link 01/2021 - 09/2018
2	regorafenibIBA 08/2014 - 10/2013
1	CalciumIBA 01/2021
1	BismuthIBA 01/2021
1	TungstenIBA 01/2021
1	HafniumIBA 01/2021
1	HolmiumIBA 01/2021
1	GasesIBA 09/2018
1	Gadolinium DTPA (Magnevist)FDA Link 09/2018
1	iotrolan (Isovist)FDA Link 12/2014
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 12/2014
1	Coloring Agents (Dyes)IBA 12/2014
1	4- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA 08/2013
1	Lipocalin-2IBA 09/2012
1	Plasminogen Activator Inhibitor 1IBA 09/2012
1	iomeprolIBA 04/2012
1	Lanthanoid Series Elements (Lanthanides)IBA 11/2011
1	ElementsIBA 11/2011
1	LigandsIBA 01/2011
1	Biomarkers (Surrogate Marker)IBA 02/2009
1	Biological ProductsIBA 02/2009
1	Phenylalanine (L-Phenylalanine)FDA Link 08/2005
1	SteamIBA 05/2003
1	LipidsIBA 05/2003
1	Protons (Proton)IBA 05/2003

Therapy/Procedure

5	Intravenous Injections 01/2017 - 01/2011
3	Radiotherapy 11/2019 - 06/2009
3	Therapeutics 10/2013 - 06/2009
2	Injections 01/2022 - 01/2020
1	DF protocol 12/2020
1	Drug Therapy (Chemotherapy) 04/2012